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A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individuals who
develop graft failure after their ﬁrst HCT. Data on outcomes after second HCT in patients with Fanconi anemia
(FA) are scarce. Here we report outcomes after second allogeneic HCT for FA (n ¼ 81). The indication for
second HCT was graft failure after the ﬁrst HCT. Transplantations were performed between 1990 and 2012.
The timing of the second HCT predicted subsequent graft failure and survival. Graft failure was high when the
second HCT was performed less than 3 months from the ﬁrst. The 3-month probability of graft failure was
69% when the interval between the ﬁrst HCT and second HCT was less than 3 months, compared with 23%
when the interval was longer (P < .001). Consequently, the 1-year survival rate was substantially lower when
the interval between the ﬁrst and second HCTs was less than 3 months compared with longer (23% vs 58%;
P ¼ .001). The corresponding 5-year probability of survival was 16% and 45%, respectively (P ¼ .006). Takenedgments on page 1794.
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M. Ayas et al. / Biol Blood Marrow Transplant 21 (2015) 1790e1795 1791together, these data suggest that fewer than one-half of patients with FA undergoing a second HCT for graft
failure are long-term survivors. There is an urgent need to develop strategies to reduce the rate of graft failure
after ﬁrst HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION overall survival were estimated for the all patients, by the interval between
Fanconi anemia (FA) cells are characterized by defects in
DNA repair and cell cycle checkpoints, which play prominent
roles in the genomic instability characteristic of this disease.
This instability leads to increased apoptosis and bone
marrow failure, as well as evolution to myelodysplastic
syndrome or acute leukemia in some patients [1-5]. Alloge-
neic hematopoietic cell transplantation (HCT) is currently
the only curative modality for the treatment of bone marrow
failure and clonal disorders in patients with FA, with excel-
lent outcomes particularly in recipients of HLA-matched
related donor HCT [6-21].
Nonetheless, graft failure is a major complication associ-
ated with a dismal prognosis, particularly in recipients of
alternative donor HCT. Second HCT is the only potential
salvage modality, although great caution must be exercised
because patients with FA may experience pronounced
toxicity and higher mortality owing to their underlying
genomic instability. Available data on the outcomes of pa-
tients with FA after second HCT are limited [12,13,16,22-24];
therefore, we studied 81 patients with FA who underwent a
second HCT for graft failure.
PATIENTS AND METHODS
Data Source
The Center for International Blood and Marrow Transplant Research is a
voluntary network ofmore than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and autologous HCT.
Onsite audits ensure compliance and data quality. Patients are followed
longitudinally until death or loss to follow-up. Patients, legal guardians, or
both provided written informed consent for research participation. The
Institutional Review Boards of the Medical College of Wisconsin and the
National Marrow Donor Program approved this study.
Patients
To be eligible, patients with FA had to have undergone a second HCT for
graft failure after their ﬁrst HCT. The indication for the initial transplantation
was marrow failure. All HCTs were performed between 1990 and 2012.
Patients with FA with acute leukemia or myelodysplastic syndrome or with
abnormal clones before either the ﬁrst or second HCT were excluded. A total
of 533 patients with FA underwent allogeneic HCT, including 432 who un-
derwent ﬁrst HCT for marrow failure. Among these 432 transplant re-
cipients, 137 experienced either primary or secondary graft failure, and of
these, only 81 underwent a second HCT (the population for the present
analysis). The remaining 56 patients with graft failure after the ﬁrst HCT did
not proceed to a second HCT; all succumbed to their disease, with a median
time to death of 1 month. The decision to offer a second HCT was at the
discretion of the transplantation center and the treating physicians.
End Points
The primary outcome was survival. Neutrophil recovery was deﬁned as
the ﬁrst of 3 consecutive days with an absolute neutrophil count (ANC) of
0.5109/L. Primary graft failure was deﬁned as failure to achieve neutrophil
recovery, and secondary graft failure was deﬁned as sustained loss of ANC
(<0.5  109/L) after initial recovery. Platelet recovery was deﬁned as
achieving an ANC of 20  109/L unsupported by platelet transfusions for at
least 7 days. Acute and chronic graft-versus-host disease (GVHD) were
graded using published criteria [25,26].
Statistical Analyses
The probability of overall survival was calculated using the Kaplan-
Meier estimator [27]. The probabilities for hematopoietic recovery and
acute and chronic GVHD were calculated using the cumulative incidence
estimator, with death as the competing risk [28]. The 5-year probabilities ofthe ﬁrst HCT and second HCT (3 vs >3 months), age at transplantation
(10 vs >10 years), performance score (90 to 100 vs <90), donor type
(related vs unrelated), same versus different donor for second HCT, and
transplantation period (before 2000 vs 2000 and after). A P value  .05 was
considered signiﬁcant; all P values are 2-sided. Analyses were performed
using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Patient, Disease, and Transplant Characteristics
Patient and transplant characteristics are listed in Table 1.
Themedian age at second HCTwas 11 years, withmost of the
second HCTs (69 of 81; 85%) occurring within 6 months of
the ﬁrst HCT. Five patients were older than 21 years. Only
22% of the patients reported a performance score of 90 or
100, and one-third of the patients reported a score of 60, 70,
or 80. Five patients were reported to have renal impairment,
3 patients had infection, and 3 patients had hepatic toxicity
(elevated transaminases) after veno-occlusive disease from
the ﬁrst HCT. Most transplant recipients received non-
eirradiation-containing regimens. Only 8% of recipients
received irradiation-containing regimens for both the ﬁrst
and second HCTs. Fludarabine was included in the condi-
tioning regimen for one-third of the HCTs. The predominant
stem cell source was an unrelated donor, accounting for
approximately 60% of transplants. Bone marrow was the
predominant graft source (47 of 81; 58%); 17 transplants
used peripheral blood (21%), and 17 used umbilical cord
blood (21%). One-third of second HCTs (n ¼ 27) used a
different donor from that used in the ﬁrst HCT. Of these, 6
used a graft from a related donor, and 21 used a graft from an
unrelated donor. Of note, 14 of the 27 recipients who
received their graft from a different donor had received
umbilical cord blood for their ﬁrst HCT.
Most GVHD prophylaxis regimens included cyclosporine
with another agent; in vivo T cell depletion (antithymocyte
globulin [ATG]) was used for 62% of the second HCTs. The
median follow-up from the second HCT was 62 months
(range, 3 to 117 months).
Approximately 60% of second HCTs were performed
within 3 months of the ﬁrst HCT; characteristics of these
transplantations are presented in Table 2. Patients under-
going HCT within 3 months of their ﬁrst HCT were more
likely to report a performance score <90, less likely to have
received a ﬂudarabine-containing regimen, and more likely
to have received their transplants from a donor different
from their ﬁrst transplant. Most second HCTs with a different
donor used an unrelated donor for the ﬁrst and second
transplants, with cord blood as the predominant stem cell
source.
Hematopoietic Recovery and Overall Survival
For the entire study population, the day 28 probability of
neutrophil recovery was 37% (95% conﬁdence interval [CI],
27% to 48%) and the day 100 probability of platelet recovery
was 30% (95% CI, 19% to 40%). The rate of primary graft
failure was high (48 of the 81 HCTs), and secondary graft
failure occurred in 4 patients. Neutrophil and platelet
Table 1
Patient and Transplantation Characteristics for Second HCT
Characteristic Value
Number of patients 81
Age at HCT, n (%)
2-10 yr 38 (47)
11-21 yr 38 (47)
22-36 yr 5 (6)
Sex, n (%)
Male 54 (67)
Female 27 (33)
Performance score, n (%)
50 30 (37)
60-80 26 (32)
90-100 18 (22)
Missing 7 (9)
Interval between ﬁrst and second HCTs, n (%)
<3 mo 50 (62)
3-4 mo 10 (12)
5-6 mo 9 (11)
7 mo 12 (15)
Conditioning regimens
Radiation-containing regimens, n (%)
Total body irradiation þ ﬂudarabine 9 (11)
Total body irradiation þ cyclophosphamide 2 (3)
Total body irradiation þ ATG 4 (5)
Total body irradiation alone 2 (3)
Total lymphocyte irradiation þ cyclophosphamide 1 (1)
Noneradiation-containing regimens, n (%)
Fludarabine þ cyclophosphamide þ ATG 15 (19)
Fludarabine and ATG 7 (9)
Fludarabine and cyclophosphamide 4 (5)
Fludarabine alone 4 (5)
Cyclophosphamide alone 8 (10)
ATG alone 14 (16)
None 11 (13)
Recipient CMV status, n (%)
Negative 25 (31)
Positive 38 (47)
Missing/not tested 18 (22)
Donor type, n (%)
HLA-identical sibling (cord blood, n ¼ 3) 17 (20)
Other mismatched relative 15 (19)
Unrelated donor HLA-matched (cord blood, n ¼ 1) 15 (19)
Unrelated donor HLA-mismatched (cord blood, n ¼ 16) 34 (42)
Year of HCT, n (%)
1990-1999 27 (33)
2000-2012 54 (67)
GVHD prophylaxis, n (%)
Ex vivo T cell depletion 12 (15)
In vivo T cell depletion 8 (10)
Tacrolimus-containing 5 (6)
Cyclosporine-containing 50 (62)
Post-transplantation cyclophosphamide 1 (1)
None 5 (6)
Follow-up of survivors, mo, median (range) 62 (3-117)
CMV indicates cytomegalovirus.
Table 2
Patient and Transplantation Characteristics by Interval between First and
Second HCTs
Characteristic Interval
<3 mo 3 mo
Number of patients 50 31
Performance score, n (%)
50 22 (44) 8 (26)
60-80 17 (34) 9 (29)
90-100 6 (12) 12 (39)
Missing 5 (10) 2 (6)
Interval between ﬁrst and second HCTs, n (%)
<3 mo 50 (100) 0
3-4 mo 0 10 (32)
5-6 mo 0 9 (29)
7 mo 0 12 (39)
Transplantation conditioning regimen, n (%)
Radiation and ﬂudarabine-containing 4 (8) 5 (16)
Nonradiation regimen with ﬂudarabine 7 (14) 10 (32)
Radiation-containing without ﬂudarabine 7 (14) 3 (10)
Nonradiation regimen without ﬂudarabine 32 (64) 13 (42)
Different donor, n (%)
Yes 20 (40) 7 (23)
No 30 (60) 24 (77)
Table 3
Results of Univariate Analysis after Second HCT by Interval between First
and Second HCTs (<3 vs 3 mo)
Outcome <3 mo 3 mo P value
N Probability
(95% CI), %
N Probability
(95% CI), %
ANC >0.5  109/L 50 31 .002
At 28 d 24 (13-37) 58 (38-73)
Graft failure
(primary or
secondary)
45 26
At 28 d 33 (20-47) 8 (1-22) .004
At 3 mo 69 (53-80) 23 (9-40) <.001
Platelets 20  109/L 45 26
At 100 days 13 (5-25) 58 (37-74) <.001
Overall survival 50 31
At 1 yr 23 (13-36) 58 (39-73) .001
At 3 yr 19 (9-31) 45 (27-61) .013
At 5 yr 16 (8-28) 45 (27-61) .006
N indicates number evaluable.
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ﬁrst and second HCTs exceeded 3 months (Table 3 and
Figure 1). Among the 50 patients who underwent retrans-
plantation within 3 months of the ﬁrst HCT, 48 did so owing
to primary graft failure and 2 did so for secondary graft
failure. Only 14 of these 50 patients achieved sustained
neutrophil recovery. Five of these 14 patients were alive at
the time of this report; the 9 deaths were attributed to
infection, GVHD, multiorgan failure, graft rejection, and
hemorrhage. In contrast, 19 of 31 patients who underwent
HCT beyond 3 months achieved sustained neutrophil re-
covery. Twelve patients were alive at the last follow-up, and
7 patients died from transplantation-related complications
(2 from graft rejection, 2 from GVHD, 2 from multiorgan
failure, and 1 from interstitial pneumonitis).The 1-year and 5-year probabilities of overall survival for
patients undergoing retransplanted within 3 months of their
ﬁrst HCT were 23% and 16%, respectively (Table 3 and
Figure 2). The corresponding probabilities for patients un-
dergoing retransplantation beyond 3 months were higher
(58% and 45%; Table 3). As expected, the 1-year and 5-year
survival rates were 17% and 13%, respectively, for patients
with a performance score <90, but 83% and 72% for those
with a performance scores of 90 or 100 (P < .0001). The
transplantation period was also associated with survival. The
5-year probability of survival was 7% (95% CI, 1% to 21%) for
patients undergoing HCT in 1990 to 1999 and 38% (95% CI,
25% to 50%) for those undergoing HCT in 2000 to 2012 (P <
.0001). We speciﬁcally tested for effects of age at second HCT,
same versus different donor for second HCT, and related
versus unrelated donor, and found none. We were unable to
test for an effect of graft type, because bone marrow was the
predominant graft. Only 3 of 17 cord blood recipients were
alive at the time of this report.
Most deaths occurred within the ﬁrst year after the sec-
ond HCT in both groups, 38 of 41 (93%) among those un-
dergoing retransplantation within 3 months of the ﬁrst HCT
Figure 1. The day 28 cumulative incidence of neutrophil recovery was 24%
(95% CI, 13% to 37%) for patients undergoing HCT within 3 months of their ﬁrst
HCT (A) and 58% (95% CI, 38% to 73%) for those undergoing HCT beyond 3
months after their ﬁrst HCT (B).
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plantation later. Although graft failure after the second HCT
was the predominant cause of death in both groups (n ¼ 42),
there were 5 GVHD-related deaths, 3 deaths from infection, 1
death from interstitial pneumonitis, 1 death from hemor-
rhage, and 2 deaths from multiorgan failure. The cause of
death was not reported in 1 patient.
Acute and Chronic GVHD
The day 100 cumulative incidence of grade II-IV acute
GVHD was 16% (95% CI, 9% to 26%), including grade II in 4
patients and grade III-IV in 7 patients. The 5-year cumulative
incidence of chronic GVHD was 11% (95% CI, 5% to 19%); it
was limited in 3 patients and extensive in 5 patients. The low
incidence of acute and chronic GVHD prevented further
subset analyses.
Post-Transplantation Malignancy
One patient developed Epstein-Barr viruseassociated
lymphoproliferative disease malignancy at 2 months after
the second HCT. This patient was alive at the last follow-up.
DISCUSSION
Graft failure represents a relatively infrequent but
potentially lethal complication of allogeneic HCT. Data on the
incidence of graft failure and subsequent management in
patients with FA are limited. Early reports indicated a graft
failure rate of 8% after HLA-matched related transplantationFigure 2. The 5-year probability of overall survival was 16% (95% CI, 8% to 28%)
for patients undergoing HCT within 3 months of their ﬁrst HCT (A) and 45%
(95% CI, 27% to 61%) for those undergoing HCT beyond 3 months after their
ﬁrst HCT (B).and conditioning with cyclophosphamide (20 mg/kg) and
thoracoabdominal irradiation (500 cGy) [14]. Others have
reported that the addition of ATG or the omission of radiation
from the conditioning regimen did not change the incidence
of graft failure, with rates varying between 7% and 13%
[8,16,22,23].
The decision to perform a second HCT after primary or
secondary graft failure for FA is challenging. The underlying
genomic instability of FA cells may render further cytotoxic
conditioning detrimental and lead to poor survival. The
present analyses identiﬁed 3 factors predictive for survival
after second HCT. When the interval between the ﬁrst and
second HCTs was less than 3 months, survival was dismal.
Poor performance score was also associated with poor sur-
vival; however, more than 75% of the patients who under-
went retransplantation within 3 months of the ﬁrst HCT had
a performance score of 80, implying that performance
score is a surrogate for the interval between ﬁrst and second
HCTs. Because themajority of patients in the present analysis
underwent retransplantation for primary graft failure, the
timing of the second HCTwas at the discretion of the treating
physician. Transplantation before the year 2000 was also
associated with lower survival compared with trans-
plantation more recent years. This effect of transplantation
period can be attributed to advances in supportive care;
however, approximately 40% of second HCTs done before
2000 were performed less than 3 months after the ﬁrst HCT.
Formal multivariate analysis was not undertaken owing to
the limited sample size. Although comorbidity data were not
systematically collected during the study period, most pa-
tients in the early retransplantation group had poor perfor-
mance scores, a surrogate marker for the burden of
comorbidities. Observations similar to ours regarding the
timing of second HCT and performance scores have been
reported for patients with severe aplastic anemia undergo-
ing a second HCT for graft failure [29].
Given the superior survival rate in patients undergoing
HCT beyond the 3-month period (1-year survival of 58% vs
23%), it might be prudent to provide supportive care and
delay offering second HCT for at least 3 months after the ﬁrst
HCT. This strategy might allow for recovery from tissue
damage suffered during the ﬁrst HCT, although patients
would be at risk of succumbing to infection. Overall survival
after primary graft failure is low. The decision to offer a
second HCT and the determination of the timing must be
made after carefully weighing the risks and beneﬁts.
One of the chief concerns when contemplating a second
HCT is the choice of themost appropriate preparative regimen.
Many regimens used for second HCTs have resulted in poor
engraftment with high mortality. The introduction of
ﬂudarabine-based conditioning regimens for FA has improved
engraftment and survival after ﬁrst HCT [12,13,15,19,20,30].
Our small sample sizepreventedamoredetailedanalysis of the
effects of the various conditioning regimens. It is noteworthy,
however, thatmost secondHCTsusednonirradiation regimens,
and approximately one-half of the regimensusedafter a longer
interval between the ﬁrst and second HCTs included ﬂudar-
abine. Similarly, our modest cohort size does not allow us to
make strong recommendations regarding second HCT condi-
tioning regimens. The choice of donor for second HCT was
largelyexplainedbywhether theﬁrst donorwasa relatedoran
unrelated donor. With unrelated donor transplants, the donor
for the second HCT was frequently different from that for the
ﬁrst HCT; this was unavoidable when the ﬁrst HCT used cord
blood as the graft source.
M. Ayas et al. / Biol Blood Marrow Transplant 21 (2015) 1790e17951794Although the present analysis shows that long-term sur-
vival is possible in approximately one-half of the patients
undergoing retransplantation more than 3 months from the
ﬁrst HCT, repeated graft failure and transplantation-related
complications are barriers to a more successful outcome.
The signiﬁcantly lower survival rate of <20% noted in pa-
tients with a shorter interval between the ﬁrst and second
HCTs raises questions regarding the justiﬁcation for sub-
jecting these patients to an early second HCT.ACKNOWLEDGMENTS
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